MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jchf.2025.01.019

Медицинская библиотека · JACC. Heart failure · 2025

First-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure: FUTURE-HF.

Kalra Paul R, Gogorishvili Irakli, Khabeishvili George, Málek Filip, Toman Ondřej, Critoph Chris, Flett Andrew S, Cowburn Peter J, Mehra Mandeep R, Sheridan William S, Britton John R, Buxo Teresa, Kealy Robyn M, Kent Annette, Greene Barry R, Guha Kaushik, Gardner Roy S, Loke Ian, Vazir Ali, Brugts Jasper J, Gray Alastair, Testani Jeffrey M, Damman Kevin

Клиническое исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Variations of inferior vena cava (IVC) area and collapsibility serve as early markers of congestion and predict risk for heart failure (HF) events.

OBJECTIVES

The aim of this first-in-human study (FUTURE-HF [First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients]) was to evaluate the safety and feasibility of a novel implantable IVC sensor for remote management in patients with HF. This paper is the final report on primary (3-month) and exploratory (6-month) endpoints.

METHODS

Patients with HF hospitalizations within the previous year, with elevated natriuretic peptide levels, and on optimal HF treatment were included. The primary safety endpoints were procedural success without device- or procedure-related complications at 3 months. The primary technical endpoint was signal acquisition following implantation and at a clinic visit within 3 months. Sensor-derived IVC area was compared with computed tomography (CT)-based IVC dimensions. Patient adherence to daily readings and exploratory clinical findings at 6 months were assessed.

RESULTS

Fifty patients underwent successful implantation (mean age 65 ± 9 years, 14% women, 72% in NYHA functional class III), with 49 contributing to the primary safety and technical endpoints at 3 months. Sensor-derived IVC area demonstrated excellent agreement with CT measurement (mean absolute error 13.53 mm2 [3.55%] R2 = 0.98). Median adherence was 96% at 6-month follow-up. Exploratory analyses of clinical outcomes suggested improvements in N-terminal pro-B-type natriuretic peptide, NYHA functional class, and quality of life and reduced HF events.

CONCLUSIONS

This first-in-human experience demonstrated that the implantation of an IVC sensor was safe and feasible. Sensor-derived IVC area demonstrated excellent correlation with CT-derived IVC area, and exploratory clinical outcomes suggest that this may serve as a novel tool for ambulatory management of congestion to facilitate remote care in HF. (First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients [FUTURE-HF]; NCT04203576).

Для цитирования: Kalra Paul R, Gogorishvili Irakli, Khabeishvili George, Málek Filip, Toman Ondřej, Critoph Chris, Flett Andrew S, Cowburn Peter J, Mehra Mandeep R, Sheridan William S, Britton John R, Buxo Teresa, Kealy Robyn M, Kent Annette, Greene Barry R, Guha Kaushik, Gardner Roy S, Loke Ian, Vazir Ali, Brugts Jasper J, Gray Alastair, Testani Jeffrey M, Damman Kevin. First-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure: FUTURE-HF.. JACC. Heart failure. 2025. DOI: 10.1016/j.jchf.2025.01.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.